'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
《FDA在重新考慮Tirzepatide短缺時，不會對GLP-1混合物廠商採取行動》- Endpoints 資訊
The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates Eli Lilly's weight loss and diabetes drug ...
FDA在星期四澄清，它在重新評估Eli Lilly的減重和糖尿病藥物時，不會針對GLP-1混合物廠商的某些違規行爲採取行動...
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。